Ras dependent paracrine secretion of osteopontin by nf1 +/- osteoblasts promote osteodast activation in a neurofibromatosis type i murine model

Pediatric Research

Volumn 65, Issue 6, 2009, Pages 613-618

  Li, Huijie ^a,b   Liu, Yaling ^a,b   Zhang, Qi ^a,b   Jing, Yongmin ^a,b   Chen, Shi ^a   Song, Zhaohui ^a,b   Yan, Jincheng ^a,b   Li, Yan ^a,c   Wu, Xiaohua ^a   Zhang, Xianghong ^a,b   Zhang, Yingze ^a,b   Case, Jamie ^a   Yu, Menggang ^a   Ingram, David A ^a   Yang, Feng Chun ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; NEUTRALIZING ANTIBODY; OSTEOPONTIN; RAS PROTEIN;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION;

ADULT; ANIMALS; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; CHILD; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; OSTEOBLASTS; OSTEOCLASTS; OSTEOPONTIN; PARACRINE COMMUNICATION; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; STEM CELLS;

EID: 67049119281     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1203/PDR.0b013e3181a1c607     Document Type: Article

References (31)

1. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K 1996 Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12:144-148
2. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG 1996 Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersen-sitivity and chronic myeloid leukaemia. Nat Genet 12:137-143
3. Yu X, Chen S, Potter OL, Murthy SM, Li J, Pulcini JM, Ohashi N, Winata T, Everett ET, Ingram D, Clapp WD, Hock JM 2005 Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone 36:793-802
4. Crawford AH Jr, Bagamery N 1986 Osseous manifestations of neurofibromatosis in childhood. J Pediatr Orthop 6:72-88
5. Kuorilehto T, Ekholm E, Nissinen M, Hietaniemi K, Hiltunen A, Paavolainen P, Penttinen R, Peltonen J 2006 NF1 gene expression in mouse fracture healing and in experimental rat pseudarthrosis. J Histochem Cytochem 54:363-370
6. Stevenson DA, Moyer-Mileur LJ, Murray M, Slater H, Sheng X, Carey JC, Dube B, Viskochil DH 2007 Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 150:83-88
7. Illes T, Halmai V, de Jonge T, Dubousset J 2001 Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities. Osteoporos Int 12:823-827
8. Stevenson DA, Zhou H, Ashrafi S, Messiaen LM, Carey JC, D'Astous JL, Santora SD, Viskochil DH 2006 Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 79:143-148
9. Teitelbaum SL 2000 Osteoclasts, integrins, and osteoporosis. J Bone Miner Metab 18:344-349
10. Yang FC, Chen S, Robling AG, Yu X, Nebesio TD, Yan J, Morgan T, Li X, Yuan J, Hock J, Ingram DA, Clapp DW 2006 Hyperaclivation of p21 and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 116:2880-2891
11. Weber GF, Cantor H 1996 The immunology of Eta-1/osteopontin. Cytokine Growth Factor Rev 7:241-248
12. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL 1998 Altered wound healing in mice lacking a functional osteopontin gene (sppl). J Clin Invest 101:1468-1478
13. Chellaiah MA, Hruska KA 2003 The integrin alpha (v) beta(3) and CD44 regulate the actions of osteopontin on osteoclast motility. Calcif Tissue Int 72:197-205
14. Shapses SA, Cifuentes M, Spevak L, Chowdhury H, Brittingham J, Boskey AL, Denhardt DT 2003 Osteopontin facilitates bone resorption, decreasing bone mineral crystallinity and content during calcium deficiency. Calcif Tissue Int 73:86-92
15. Standal T, Borset M, Sundan A 2004 Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26:179-184
16. Chellaiah MA, Kizer N, Biswas R, Alvarez U, Strauss-Schoenberger J, Rifas L, Rittling SR, Denhardt DT, Hruska KA 2003 Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 14:173-189
17. Yoshitake H, Rittling SR, Denhardt DT, Noda M 1999 Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA 96:8156-8160
18. Wu X, Estwick SA, Chen S, Yu M, Ming W, Nebesio TD, Li Y, Yuan J, Kapur R, Ingram D, Yoder MC, Yang FC 2006 Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells. Hum Mol Genet 15:2837-2845
19. Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW 2001 Neurofibromin GTPase-activating protein-related domains restore normal growth in Nfl -/- cells. J Biol Chem 276:7240-7245
20. Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP 2005 Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J Bone Miner Res 20:1659-1668
21. Kolanczyk M, Kossler N, Kuhnisch J, Lavitas L, Stricker S, Wilkening U, Man-jubala I, Fratzl P, Sporle R, Herrmann BG, Parada LF, Kornak U, Mundlos S 2007 Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet 16:874-886
22. Ishii T, Ohshima S, Ishida T, Mima T, Tabunoki Y, Kobayashi H, Maeda M, Uede T, Liaw L, Kinoshita N, Kawase I, Saeki Y 2004 Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. Biochem Biophys Res Commun 316:809-815
23. Sugatani T, Alvarez UM, Hruska KA 2003 Activin A stimulates IkappaB-alpha/ NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem 90:59-67
24. Rangaswami H, Bulbule A, Kundu GC 2005 JNK1 differentially regulates osteopon-tin-induced nuclear factor-inducing kinase/MEKKl-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation. J Biol Chem 280:19381-19392
25. Scherpereel A, Lee YC 2007 Biomarkers for mesothelioma. Curr Opin Pulm Med 13:339-443
26. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS 2006 The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 17:463-474
27. Gutmann DH, Wu YL, Hedrick NM, Zhu Y, Guha A, Parada LF 2001 Heterozy-gosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes. Hum Mol Genet 10:3009-3016
28. Gingery A, Bradley E, Shaw A, Oursler MJ 2003 Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem 89:165-179
29. Abbas S, Clohisy JC, Abu-Amer Y 2003 Mitogen-activated protein (MAP) kinases mediate PMMA-induction of osteoclasts. J Orthop Res 21:1041-1048
30. Digilio MC, Sarkozy A, Capolino R, Chiarini Testa MB, Esposito G, de Zorzi A, Cutrera R, Marino B, Dallapiccola B 2008 Costello syndrome: clinical diagnosis in the first year of life. Eur J Pediatr 167:621-628
31. Hou JW 2008 Rapidly progressive scoliosis after successful treatment for osteopenia in Costello syndrome. Am J Med Genet A 146:393-396